Cargando…
Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138496/ https://www.ncbi.nlm.nih.gov/pubmed/35625828 http://dx.doi.org/10.3390/biomedicines10051091 |
_version_ | 1784714636755468288 |
---|---|
author | Bonanni, Michela Rehak, Laura Massaro, Gianluca Benedetto, Daniela Matteucci, Andrea Russo, Giulio Esperto, Francesco Federici, Massimo Mauriello, Alessandro Sangiorgi, Giuseppe Massimo |
author_facet | Bonanni, Michela Rehak, Laura Massaro, Gianluca Benedetto, Daniela Matteucci, Andrea Russo, Giulio Esperto, Francesco Federici, Massimo Mauriello, Alessandro Sangiorgi, Giuseppe Massimo |
author_sort | Bonanni, Michela |
collection | PubMed |
description | About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich plasma (PRP), are currently under investigation. Recent data point out that the regenerative capacity of stem cells is strongly influenced by local immune responses, with macrophages playing a pivotal role in the injury response and as a coordinator of tissue regeneration, suggesting that control of the immune response could be an appealing approach in regenerative medicine. A new generation of autologous cell therapy based on immune cells instead of stem cells, which could change regenerative medicine for good, is discussed. Increasing safety and efficacy data are coming from clinical trials using peripheral blood mononuclear cells to treat no-option critical limb ischemia and diabetic foot. In this review, ongoing phase 1/phase 2 stem cell clinical trials are discussed. In addition, we examine the mechanism of action and rationale, as well as propose a new generation of regenerative therapies, evolving from typical stem cell or growth factor to immune cell-based medicine, based on autologous peripheral blood mononuclear cells (PBMNC) concentrates for the treatment of ED. |
format | Online Article Text |
id | pubmed-9138496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91384962022-05-28 Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? Bonanni, Michela Rehak, Laura Massaro, Gianluca Benedetto, Daniela Matteucci, Andrea Russo, Giulio Esperto, Francesco Federici, Massimo Mauriello, Alessandro Sangiorgi, Giuseppe Massimo Biomedicines Review About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich plasma (PRP), are currently under investigation. Recent data point out that the regenerative capacity of stem cells is strongly influenced by local immune responses, with macrophages playing a pivotal role in the injury response and as a coordinator of tissue regeneration, suggesting that control of the immune response could be an appealing approach in regenerative medicine. A new generation of autologous cell therapy based on immune cells instead of stem cells, which could change regenerative medicine for good, is discussed. Increasing safety and efficacy data are coming from clinical trials using peripheral blood mononuclear cells to treat no-option critical limb ischemia and diabetic foot. In this review, ongoing phase 1/phase 2 stem cell clinical trials are discussed. In addition, we examine the mechanism of action and rationale, as well as propose a new generation of regenerative therapies, evolving from typical stem cell or growth factor to immune cell-based medicine, based on autologous peripheral blood mononuclear cells (PBMNC) concentrates for the treatment of ED. MDPI 2022-05-08 /pmc/articles/PMC9138496/ /pubmed/35625828 http://dx.doi.org/10.3390/biomedicines10051091 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bonanni, Michela Rehak, Laura Massaro, Gianluca Benedetto, Daniela Matteucci, Andrea Russo, Giulio Esperto, Francesco Federici, Massimo Mauriello, Alessandro Sangiorgi, Giuseppe Massimo Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? |
title | Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? |
title_full | Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? |
title_fullStr | Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? |
title_full_unstemmed | Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? |
title_short | Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? |
title_sort | autologous immune cell-based regenerative therapies to treat vasculogenic erectile dysfunction: is the immuno-centric revolution ready for the prime time? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138496/ https://www.ncbi.nlm.nih.gov/pubmed/35625828 http://dx.doi.org/10.3390/biomedicines10051091 |
work_keys_str_mv | AT bonannimichela autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT rehaklaura autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT massarogianluca autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT benedettodaniela autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT matteucciandrea autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT russogiulio autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT espertofrancesco autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT federicimassimo autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT maurielloalessandro autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime AT sangiorgigiuseppemassimo autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime |